115 results
Page 3 of 6
6-K/A
EX-99.1
g8hz sx0f
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K
EX-99.1
8o2uc vz26nk
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-99.2
h9ju klamdzhqn4mq9
5 Aug 21
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
6-K
EX-99.1
e8q1comzhfzsblpdl7q
27 Jul 21
Current report (foreign)
6:12am
6-K
EX-99.2
g91o3
1 Jun 21
ObsEva SA Announces that Shareholders Approved all Board Proposals at its
6:30am
6-K
EX-99.1
7mfenq n61
20 May 21
ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of
6:30am
6-K
EX-99.1
q0o2y35 846w7wydtj13
6 May 21
ObsEva appoints Clive Bertram as Chief Commercial Officer
6:05am
6-K
EX-99.3
bzoam9
6 May 21
Index to Unaudited Condensed Consolidated Financial Statements
6:03am
6-K
EX-99.2
idbr zavs
6 May 21
Index to Unaudited Condensed Consolidated Financial Statements
6:03am
6-K
EX-99.1
0vt9c8e
31 Mar 21
Current report (foreign)
7:15am
424B5
g491v68d6pc1l6tdilx
5 Mar 21
Prospectus supplement for primary offering
7:55am
6-K
EX-99.1
bzdmc5qwjdaqw
5 Mar 21
ObsEva Announces Year End 2020 Financial Results
7:21am
6-K
EX-99.2
th8suwhvk qxhuwm5m
17 Feb 21
ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference
6:04am
6-K
EX-99.1
8gk m6xn6sl0l5
10 Feb 21
ObsEva Provides Business Outlook for 2021
6:10am
6-K/A
EX-99.1
fq2gb9ssjloyxeun1
19 Jan 21
Current report (foreign) (amended)
6:25am
6-K
EX-99.1
hvu3u bnweky50gce
13 Jan 21
Current report (foreign)
4:00pm
6-K
EX-99.1
mr0jq4ylp1ez1 i1cf83
11 Jan 21
ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program
7:05am
6-K
EX-99.1
oc87jbcbgwu1ks64k
4 Jan 21
ObsEva appoints David Renas as Chief Financial Officer
6:36am
6-K
EX-99.2
1kmgx0komnu 22t9u6uu
10 Dec 20
Current report (foreign)
6:03am